(Reuters) - Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs.
Lilly will test its treatments - approved and experimental - in combination with PD-1 inhibitors Keytruda and Opdivo.
20:05 Headphone deal of the day: Klipsch Reference On-Ear Premium headphone for $3011
11:32 Brexit: EU negotiator says 'time's short' for reaching deal13
09:13 Rouhani says Iran will not let Trump rip up nuclear deal13
06:21 Carlos Beltran agrees to one-year deal with Houston Astros16